

## DAFTAR PUSTAKA

- Adair, C.G., Bridges, J.M., Desai, Z.R., 1986, Can food affect the bioavailability of chlorambucil in patients with haematological malignancies? *Cancer Chemother, Pharmacol*, 17, 99–102.
- Aisner, J., 2007, Overview of the changing paradigm in cancer treatment: oral chemotherapy, *Am J Health Syst Pharm*, 64, S4-7.
- Alkan, A., Yaşar, A., Karcı, E., Köksoy, E.B., Ürün, M., Şenler, F.Ç., Ürün, Y., Tuncay, G., Ergün, H., Akbulut, H., 2017, Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients, *Support Care Cancer*, 25, 229–236.
- Anonim, 2019, *Paclitaxel*, <https://www.drugs.com/search.php?searchterm=paclitaxel&a=1>, diakses pada November 2019.
- Aslama, A. W., 2018, *Identifikasi Drug Related Problems (DRPs) Kategori Ketidaktepatan Dosis, Kontraindikasi dan Interaksi Obat pada Pasien Kanker Payudara di Instalasi Rawat Inap RSUD Dr. Moewardi Tahun 2018*, Skripsi, Fakultas Farmasi Universitas Muhammadiyah Surakarta, Surakarta.
- Balis FM, 1986, Pharmacokinetic drug interactions of commonly used anticancer drugs, *Clin Pharmacokinet*, 11, 223-235.
- Baxter, K., Stockley, I.H. (Eds.), 2008, *Stockley's drug interactions: a source book of interactions, their mechanisms, clinical importance, and management*, 8th ed., Pharmaceutical Press, London.
- Baskar, R., Lee K. A., Yeo, R., Yeoh, K. W., 2012, Cancer and Radiation Therapy: Current Advances and Future Directions, *International Journal of Medical Sciences*.
- Beijnen JH, Schellens JH, 2004, Drug interactions in oncology. *Lancet Oncol*, 5:489-496.
- Bezabeh, S., Mackey, A. C., Kluetz, P., Jappar, D., Korvick, J., 2012, Accumulating Evidence for a Drug-Drug Interaction Between Methotrexate and Proton Pump Inhibitor, *The Oncologist*, 17, 550-554.
- Blix, H.S., Viktil, K.K., Reikvam, Øsmund, Moger, T.A., Hjemaas, B.J., Pretsch, P., Vraalsen, T.F., Walseth, E.K., 2004, The majority of hospitalised patients have drug-related problems: results from a prospective study in general hospitals, *Eur J Clin Pharmacol*, 60, 651–658.
- Blower, P., de Wit, R., Goodin, S., Aapro, M., 2005, Drug-drug interactions in oncology: why are they important and can they be minimized?, *Crit. Rev. Oncol. Hematol*, 55, 117–142.
- Buajordet, I., Ebbesen, J., Erikssen, J., Brørs, O., Hilberg, T., 2001a, Fatal adverse drug events: the paradox of drug treatment, *J. Intern. Med*, 250, 327–341.
- Buajordet, I., Ebbesen, J., Erikssen, J., Brørs, O., Hilberg, T., 2001b, Fatal adverse drug events: the paradox of drug treatment, *J Intern Med*, 250, 327–341.
- Cancer Council Australia, 2019, *Cancer Treatment*, <https://www.cancer.org.au/about-cancer/treatment/>, diakses pada 21 November 2019.
- Cascorbi, I., 2012, Drug interactions--principles, examples and clinical consequences, *Dtsch Arztebl Int*, 109, 546–555.



- Castro-Manzanares, M., do Pazo-Oubiña, F., Rodríguez-Rincón, R.M., 2019. Prevalence of potential drug–drug interactions in outpatients on treatment with parenteral antineoplastic drugs, *Int J Clin Pharm*, 41, 1429–1433.
- Chizuka, A., Suda, M., Kami, M., 2006, Difference between hematological malignancy and solid tumor research articles published in four major medical journals, *Leukemia*, 20, 1655-1657.
- Corrie, K., Hardman, J.G., 2017, Mechanisms of drug interactions: pharmacodynamics and pharmacokinetics, *Anaesthesia & Intensive Care Medicine*, 18, 331–334.
- Davidson KW, Kahn A, Price RD, 1987, Reduction of adverse drug reactions by computerized drug interaction screenin, *J Fam Pract*, 25, 371–375.
- Druker, B. J., Talpaz, M., Debra, J., Resta, R.N., Peng, Bin, 2001, Efficacy and safety of a spesific inhibitor of the ABCR-ABL tyrosine kinase in chronis myelod leukemia, *N Engl J Med*, 344, 1031-1037.
- Demetri, G.D., von Mehren, M., Blanke, C.D., Van den Abbeele, A.D., 2002, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumor, *N Engl J Med*, 347, 472-480.
- Fadilah, I. N., 2012, *Evaluasi Drug Related Problems (DRPs) kategori obat salah, dosis rendah, dosis tinggi dan interaksi obat pada pasien kanker payudara di instalasi rawat inap RSUD "X" tahun 2010*, Skripsi, Fakultas Farmasi Universitas Muhammadiyah Surakarta, Surakarta.
- Florea, A.M., Busselberg, D., 2011, Cisplatin as an anti tumor drug- cellular mechanisms of activity, drug resistanceand induced side effects, *National Library of Med*, 3 (1), 1351-1371.
- Ergun, Y., Yildirim Ozdemir, N., Toptas, S., Kurtipek, A., Eren, T., Yazici, O., Sendur, M.A., Akinci, B., Ucar, G., Oksuzoglu, B., Uncu, D., 2019, Drug-drug interactions in patients using tyrosine kinase inhibitors: A multicenter retrospective study, *J BUON* 24, 1719–1726.
- Gianni, L., Vigano, L., Locatelli, A., Capri, G., Giani, A., Tarenzi, E., Bonadonna, G., 1997, Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer, *J Cllin Oncol*, 15 (5), 1906-1915.
- Girre, V., Arkoub, H., Puts, M.T.E., Vantelon, C., Blanchard, F., Droz, J.P., Mignot, L., 2011, Potential drug interactions in elderly cancer patients. Critical Reviews in Oncology/Hematology 78, 220–226.
- Goodman, L.S., Brunton, L.L., Chabner, B., Knollmann, B.C. (Eds.), 2011. *Goodman & Gilman's pharmacological basis of therapeutics*, 12th ed. McGraw-Hill, New York.
- Hamid, M., Lashari, B., Ahsan, I., Micaily, I., Sarwar, U., Crocetti, J., 2018, A deadly prescription: combination of methotrexate and trimethoprim-sulfamethoxazole, *Journal of Community Hospital Internal Medicine Perspectives*, 8 (3), 149-151.
- Herr RD, Caravati EM, Tyler LS, 1992, Prospective evaluation of adverse drug interactions in the emergency department, *Ann Emerg Med*, 21, 1331–1336.



- Hoemme, A., Barth, H., Haschke, M., Krähenbühl, S., Strasser, F., Lehner, C., von Kameke, A., Wälti, T., Thürlimann, B., Früh, M., Driessen, C., Joerger, M., 2019, Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer, *Cancer Chemother Pharmacol*, 83, 763–774.
- Jamani, R., Lee, E.K., Berry, S.R., Saluja, R., DeAngelis, C., Giotis, A., Emmenegger, U., 2016, High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate, *Eur J Clin Pharmacol*, 72, 1391–1399.
- Jordan, K., Feyer, P., Höller, U., Link, H., Wörmann, B., Jahn, F., 2017, Supportive Treatments for Patients with Cancer, *Dtsch Arztebl Int*, 114, 481–487.
- Karadeniz, A., Simsek, N., Karakus, E., Ylidrim, S., Kara, A., Can, I., Kisa, F., Emr, H., Turkeli, M., 2011, Royal jelly modulates oxidativ stress and apoptosis in liver and kidneys of rats treated with cisplatin, *Nat Lib of Med*, 981793.
- Katzung, B.G., 2010, *Basic & clinical pharmacology*, McGraw-Hill.
- Kementerian Kesehatan RI, 2018, *infoDATIN*, Kementerian Kesehatan RI, Jakarta.
- Khan, Q., Ismail, M., Khan, S., 2017, Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study, *BMC Pharmacol Toxicol*, 18, 75.
- Knight, Wade S, Balducci L, 2004, Prevalence and outcomes of anemia in cancer: a systematic review of the literature, *Am J Med*, 116, 11S–26S.
- Koomanan, N., Ko, Y., Yong, W.-P., Ng, R., Wong, Y.-P., Lim, S.-W., Salim, A., Chan, A., 2012, Clinical Impact of Drug–Drug Interaction Between Aspirin and Prednisolone at a Cancer Center, *Clinical Therapeutics*, 34, 2259–2267.
- Kusuma, A. N. P., Andrajati, R., Andalusia, R., 2015, Analisis drug related problems pada pasien kanker padat stadium lanjut yang menjalani terapi paliatif di Rumah Sakit Kanker Dharmais, *Indonesian Journal of Cancer*, 9 (2), 49–58.
- Lemachatti, J., Levêque, D., Beretz, L., Bergerat, J.P., 2009, Potential pharmacokinetic interactions affecting antitumor drug disposition in cancer patients, *Anticancer Re.*, 29, 4741–4744.
- Lohr LK, 2009, Drug interactions with newer oral chemotherapy agents, *US Pharm*, (7)(Oncology suppl),4–8.
- Lopez-Martin, C., Garrido Siles, M., Alcaide-Garcia, J., Faus Felipe, V., 2014, Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience, *Int J Clin Pharm*, 36, 1251–1259.
- Miranda, V., Fede, A., Nobuo, M., Ayres, V., Giglio, A., Miranda, M., Riechelmann, R.P., 2011, Adverse Drug Reactions and Drug Interactions as Causes of Hospital Admission in Oncology, *Journal of Pain and Symptom Management*, 42, 342–353.
- Moghaddas, A., Adib-Majlesi, M., Sabzghabae, A.M., Hajigholami, A., Riechelmann, R., 2020, Potential drug–drug Interactions in hospitalized cancer patients: A report from the Middle-East, *J Oncol Pharm Pract* 107815522091020.



- Mouzon, A., Kerger, J., D'Hondt, L., Spinewine, A., 2013, Potential Interactions with Anticancer Agents: A Cross-Sectional Study, *Chemotherapy*, 59, 85–92.
- National Cancer Institute, 2019, *NCI Dictionary of Cancer*, <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cancer>, diakses pada 19 November 2019.
- National Cancer Institute, 2019, *Types of Cancer Treatment*, <https://www.cancer.gov/about-cancer/treatment/types>, diakses pada 20 November 2019.
- National Cancer Institute, 2020, *NCI Dictionary of Palliative Therapy*, <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/palliative-therapy>, diakses pada 22 Juni 2020.
- Nightingale, G., Pizzi, L.T., Barlow, A., Barlow, B., Jacisin, T., McGuire, M., Swartz, K., Chapman, A., 2018, The prevalence of major drug-drug interactions in older adults with cancer and the role of clinical decision support software, *Journal of Geriatric Oncology*, 9, 526–533.
- Popa, M.A., Wallace, K.J., Brunello, A., Extermann, M., Balducci, L., 2014, Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy, *Journal of Geriatric Oncology*, 5, 307–314.
- Puts, M.T.E., Monette, J., Girre, V., Costa-Lima, B., Wolfson, C., Batist, G., Bergman, H., 2010, Potential Medication Problems in Older Newly Diagnosed Cancer Patients in Canada during Cancer Treatment: A Prospective Pilot Cohort Study. *Drugs & Aging*, 27, 559–572.
- Ramos-Esquivel, A., Viquez-Jaikel, Á., Fernández, C., 2017, Potential Drug-Drug and Herb-Drug Interactions in Patients With Cancer: A Prospective Study of Medication Surveillance, *JOP*, 13, e613–e622.
- Riechelmann, R.P., Moreira, F., Smaletz, O., Saad, E.D., 2005, Potential for drug interactions in hospitalized cancer patients. *Cancer Chemother, Pharmacol*, 56, 286–290.
- Riechelmann, R.P., Tannock, I.F., Wang, L., Saad, E.D., Taback, N.A., Krzyzanowska, M.K., 2007, Potential Drug Interactions and Duplicate Prescriptions Among Cancer Patients, *JNCI Journal of the National Cancer Institute*, 99, 592–600.
- Riechelmann, R.P., Zimmermann, C., Chin, S.N., Wang, L., O'Carroll, A., Zarinehbab, S., Krzyzanowska, M.K., 2008, Potential Drug Interactions in Cancer Patients Receiving Supportive Care Exclusively, *Journal of Pain and Symptom Management*, 35, 535–543.
- Riu-Viladoms, G., Carcelero San Martín, E., Martín-Conde, M.T., Creus, N., 2019, Drug interactions with oral antineoplastic drugs: The role of the pharmacist, *Eur J Cancer Care*, 28, e12944.
- Rompelman, F.M., Smit, A.A., Franssen, E.J., Crul, M., 2017, Drug–drug interactions of cytostatics with regular medicines in lung cancer patients. *J Oncol Pharm Pract*, 23, 483–490.
- Sarwar, M.R., Dar, A.-R., Mahar, S.Y., Riaz, T., Danish, U., Iftikhar, S., 2018, Assessment of prescribing potentially inappropriate medications listed in Beers criteria and its association with the unplanned hospitalization: a cross-sectional study in Lahore, Pakistan, *CIA Volume* 13, 1485–1495.



- Scripture, C.D., Figg, W.D., 2006, Drug interactions in cancer therapy, *Nat. Rev. Cancer*, 6, 546–558.
- Shinoda, Y., Kimura, M., Usami, E., Asano, H., dan Yoshimura, T., 2016, Potential drug interaction between paclitaxel and clopidogrel, *Biomedical Reports*.
- Skeel, R. T., 2007, *Handbook of Cancer Chemotherapy*, 7th ed, Lippincott, Ohio.
- Sokol, K.C., Knudsen, J.F., Li, M.M., 2007, Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management, *J Clin Pharm Ther*, 32, 169–175.
- Stoll, P., Kopittke, L., 2015, Potential drug–drug interactions in hospitalized patients undergoing systemic chemotherapy: a prospective cohort study, *Int J Clin Pharm*, 37, 475–484.
- Sudoyo, Aru W., 2006, *Ilmu Penyakit Dalam*, Penerbitan Departemen Ilmu Penyakit Dalam FKUI, Jakarta.
- Sukardja, dan Gede, I D., 2000, *Onkologi Klinik*, Airlangga University Press, Surabaya.
- Sweetman SC, 2005, *Martindale: The Complete Drug Reference*, 34th ed, Pharmaceutical Press, Inggris.
- Tatro, D.S., 2009, *Drug Interaction Facts: The Authority on Drug Interactions*, Wolters Kluwer Health.
- Tavakoli-Ardakani, M., Kazemian, K., Salamzadeh, J., Mehdizadeh, M., 2013, Potential of Drug Interactions among Hospitalized Cancer Patients in a Developing Country, *Iran J Pharm Res*, 12, 175–182.
- Tavousi, F., Sadeghi, A., Darakhshandeh, A., Moghaddas, A., 2019, Potential Drug-drug Interactions at a Referral Pediatric Oncology Ward in Iran: A Cross-sectional Study, *Journal of Pediatric Hematology/Oncology*, 41, e146–e151.
- Thompson, M. E., Highley, M. S., 2003, Interaction between paclitxel and warfarin, *Annals of Oncology*, 14 (3), 500.
- Tjay, T. H., dan Rahardja, K., 2007, *Obat-obat penting: khasiat, penggunaan dan efek-efek sampingnya*, Elex Media Komputindo, Jakarta.
- van Leeuwen, R.W., Swart, E.L., Boom, F.A., Schuitenmaker, M.S., Hugtenburg, J.G., 2010, Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method, *BMC Cancer*, 10, 679.
- van Leeuwen, R. W. F., Brundel, D.H.S., Neef, C., van Gelder, T., Mathijssen, R.H.J., Burger, D.M., Jansman, F.G.A., 2013, Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs, *Br. J. Cancer*, 108, 1071–1078.
- van Leeuwen, R.W.F., Jansman, F.G.A., van den Bemt, P.M.L.A., de Man, F., Piran, F., Vincenten, I., Jager, A., Rijneveld, A.W., Brugma, J.D., Mathijssen, R.H.J., van Gelder, T., 2015, Drug–drug interactions in patients treated for cancer: a prospective study on clinical interventions, *Annals of Oncology*, 26, 992–997.
- van Leeuwen, R.W.F., Swart, E.L., Boven, E., Boom, F.A., Schuitenmaker, M.G., Hugtenburg, J.G., 2011, Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method, *Annals of Oncology*, 22, 2334–2341.



- Vecchia, S., Orlandi, E., Confalonieri, C., Damonti, E., Riva, A., Sartori, A., Cavanna, L., 2018, Prevalence study on potential drug–drug interaction in cancer patients in Piacenza hospital’s Onco-Haematology department, *J Oncol Pharm Pract*, 24, 490–493.
- Voll, M.L., Yap, K.D., Terpstra, W.E., Crul, M., 2010, Potential drug–drug interactions between anti-cancer agents and community pharmacy dispensed drugs, *Pharm World Sci*, 32, 575–580.
- Wang, W., Xiao, B., Liu, Z., Wang, D., Zhu, M., 2019, The Prevalence of the Potential Drug-Drug Interactions Involving Anticancer Drugs in China: A Retrospective Study, *Iran. J. Public Health*, 48, 435–443.
- World Health Organization, 2019, *Cancer*, <https://www.who.int/topics/cancer/en/>, diakses pada 22 November 2019.
- Yayasan Kanker Indonesia, 2019, *Jenis-Jenis Kanker*, <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cancer>, diakses pada 20 November 2019.
- Yap KY, Chui WK, Chan A, 2008, Drug interactions between chemotherapeutic regimens and antiepileptics, *Clin Ther*, 30, 1385-14